ANTI-FOXC2

Description_x000D_ Immunogen_x000D_ synthetic peptide corresponding to amino acids 439-454 of mouse FOXC2, conjugated to KLH via an N-terminal added lysine residue. The immunizing sequence is conserved in human and mouse. The sequence is partially conserved in FOXC1, another member of Forkhead family._x000D_ Application_x000D_ Anti-FOXC2 antibody produced in rabbit is suitable for microarray and western blotting at a concentration of 1-2μg/mL using total extracts of NIH3T3-L1 cells._x000D_ Physical form_x000D_ Solution in 0.01 M phosphate buffered saline, pH 7.4, and 15 mM sodium azide._x000D_ Disclaimer_x000D_ Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals._x000D_ Biochem/physiol Actions_x000D_ Forkhead box protein C2 (FOXC2) is a protein encoded by the FOXC2 gene in humans. It is a member of the fork head box (FOX) family of transcription factors and acts as a positive transactivator. FOXC2 is expressed in somitic mesoderm, the endocardium and blood vessels as well as the condensing mesenchyme of the bones and kidney and in head mesenchyme. It induces epithelial-to-mesenchymal transition (EMT), which is an important step in Extrahepatic cholangiocarcinoma (EHCC) invasion and metastasis. FOXC2 may act as a promising molecular target for regulating EHCC metastasis. It is mutated in the human vascular disease lymphedema-distichiasis and plays an essential role in lymphatic vascular development. FOXC2 gene expression may provide an effective target for anti-EMT-based therapies for the treatment of claudin-low/basal B breast tumors or other EMT-/CSC-enriched tumors.